Assessing the Levels of Chemotherapy-Induced Peripheral Neuropathy Using a Point-of-Nerve Conduction Device (NeuroMetrix) and the Rydel-Seiffer Tuning Fork in Patients Receiving Electroacupuncture Therapy

Inclusion Criteria

• Must have undergone chemotherapy with taxane and/or platinum agent
• Presence of numbness, paresthesias, loss of deep tendon reflexes, or other symptoms in the lower extremities those were absent prior to treatment with neurotoxic chemotherapy
• Three or more months status post platinum containing chemotherapy completion
• Grade >= 1 level of CIPN that is determined by the National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events

Exclusion Criteria

• Peripheral neuropathy from causes other than chemotherapy, such as documented * Nerve compression (carpal tunnel syndrome, sciatica, etc) * Previously known leptomeningeal carcinomatosis * Evidence of disease in the brain or spine by prior imaging
• Comorbidities with documented pre-existing neuropathy prior to the chemotherapy such as * Diabetes (HbA1c 6.5% or greater) * Human immunodeficiency virus (HIV) * Multiple myeloma * Alcoholism
• Pain medication dosing, including opioids, anti-convulsants, and anti- depressants, has been increased due to worsening symptoms less than two weeks prior to study registration
• Current use of acupuncture (manual or electro acupuncture)
• Pregnancy
• Cardiac issues (American Heart Association [AHA] class 3 or greater)
• Pacemaker or an imbedded neural stimulator
• Full therapeutic anticoagulation or an international normalized ratio (INR) > 1.4
• Currently undergoing chemotherapy with a platinum agent or have received a platinum chemotherapy agent in the past 3 months